Search results
Results from the WOW.Com Content Network
Ribociclib, sold under the brand name Kisqali, is a medication used for the treatment of certain kinds of breast cancer. [4] Ribociclib is a kinase inhibitor. [ 4 ] It was developed by Novartis and Astex Pharmaceuticals .
The Food and Drug Administration expanded the approval of Kisqali, a drug for metastatic breast cancer, to also treat patients with earlier stages of the disease, drugmaker Novartis said Tuesday.
Another remaining question surrounding CDK inhibitors as a therapy is if certain cancers will evade or be resistant to treatment. One study showed that 20% of the patients being treated for metastatic ER+ HER2-breast cancer did not respond at all to treatment with a CDK4/6 inhibitor due to preexisting mutations allowing the cancer cells to continue proliferating despite treatment with the drug ...
Another one is cancer drug Kisqali, whose revenue landed at $717 million for the period, up 45% compared to the year-ago quarter. Of Novartis' 20 top brands, 14 grew their sales on a year-over ...
Astex Pharmaceuticals is a biotechnology company focused on the discovery and development of drugs in oncology and diseases of the central nervous system.Astex was founded in 1999 by Sir Tom Blundell, [1] [2] Chris Abell & Harren Jhoti, [3] and is located in Cambridge, England.
This multi-page article lists pharmaceutical drugs alphabetically by name. Many drugs have more than one name and, therefore, the same drug may be listed more than once. ...
Combination therapy or polytherapy is therapy that uses more than one medication or modality. Typically, the term refers to using multiple therapies to treat a single disease, and often all the therapies are pharmaceutical (although it can also involve non-medical therapy, such as the combination of medications and talk therapy to treat depression).
Palbociclib, sold under the brand name Ibrance among others, is a medication developed by Pfizer for the treatment of HR-positive and HER2-negative breast cancer.It is a selective inhibitor of the cyclin-dependent kinases CDK4 and CDK6.